ASND — Ascendis Pharma A/S
$243.37+0.16%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ASND in the TickerWise workspace.
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: DK
- Exchange: NASDAQ
- Employees: 1,017
- Website: https://ascendispharma.com
Latest SEC filings for ASND
Latest ASND news
- Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026 Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.